common.study.topics.clinical

Circulating Tumor Cells in Patients with Rectal Cancer

common.study.values.description

Circulating Tumor Cells in Patients With Rectal Cancer

Objectives: - To establish the rate of circulating tumor cells (CTC) positivity in patients with locally-advanced rectal cancer (LARC), relative to other stages; - To assess changes in detected CTCs associated with neoadjuvant therapy in patients with LARC; - To correlate CTC counts with neoadjuvant treatment response as an indicator of disease risk.

common.study.values.location

participant.ui.study.affiliations-map.online-study.header-virtual

participant.ui.study.affiliations-map.online-study.text

participant.ui.study.affiliations-map.legend.locations participant.ui.study.affiliations-map.legend.selected

common.study.values.methods

No pharmaceutical medication involved common.study.methods.has-drugs-no
Patients and healthy individuals accepted common.study.methods.is-healthy-no

Procedure - Blood Draws

Healthy Participants: Blood (about 2 tablespoons) drawn at 1 time point. Rectal Cancer Participants: Blood (about 2 tablespoons) drawn 1 time before participant starts treatment. Blood also drawn: Just before tumor surgery 1-8 weeks after surgery, or before chemotherapy begins 1-12 weeks after last dose of chemotherapy year after surgery, OR 1 year after completion of treatment if no surgery years after surgery, OR 2 years after completion of treatment if no surgery If the disease gets worse dur ...read more on ClinicalTrials.org

participant.views.study.view.additional

participant.views.study.view.scientific-title

Circulating Tumor Cells in Patients With Rectal Cancer

common.study.values.clinical-trial-id

NCT02874885

participant.views.study.view.id

RdGxJe